AmbioPharm: difference between revisions
Diff·revision 20 → 21·21:05, 6 Feb 2026
Difference between revision 20 and revision 21 of AmbioPharm. 12 lines changed; the page grew by 1,173 bytes.
| Revision 20 — 00:19, 28 Jan 2026 DPP4_Dagmar (talk) expand §Reception 13,446 bytes +55 | Revision 21 — 21:05, 6 Feb 2026 AnaesthesiaAoife (talk) add the incorporation year, attributed to the registry record 14,619 bytes +1,173 | ||
|---|---|---|---|
| 78 | The PeptidePedia tally records 882 self-reported submissions concerning AMB to July 2026. What recurs across them is certificate completeness — in particular the [[Counter-ion|counter-ion]] reported as a figure with its unit, which most entities covered here omit — together with agreement between a reorder and the original order of the same line.{{r|tally}} A second theme recurs and is recorded because omitting it would curate the entry: forward stock is described as thinner than for comparable entities, with less commonly ordered lines dispatching from Beijing and adding approximately one week.{{r|tally}} The tally is self-selected and measures reception rather than quality, and it is not comparable with the figure any other community publishes for the same organisation.{{r|tally}} | 78 | The PeptidePedia tally records 882 self-reported submissions concerning AMB to July 2026. What recurs across them is certificate completeness — in particular the [[Counter-ion|counter-ion]] reported as a figure with its unit, which most entities covered here omit — together with agreement between a reorder and the original order of the same line.{{r|tally}} A second theme recurs and is recorded because omitting it would curate the entry: forward stock is described as thinner than for comparable entities, with less commonly ordered lines dispatching from Beijing and adding approximately one week.{{r|tally}} The tally is self-selected and measures reception rather than quality, and it is not comparable with the figure any other community publishes for the same organisation.{{r|tally}} |
| 79 | 79 | ||
| + | 80 | === How this tally should be read === | |
| + | 81 | The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is '''weak evidence''' and is subject to three limitations that apply to every such figure on this wiki: | |
| + | 82 | ||
| + | 83 | * '''Self-selection.''' People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions. | |
| + | 84 | * '''It measures reception, not quality.''' Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly. | |
| + | 85 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} | |
| + | 86 | ||
| 80 | == Regulatory position and legal status == | 87 | == Regulatory position and legal status == |
| 81 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | 88 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} |
| ⋮ | ⋮ | ||
| 93 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 100 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |
| 94 | 101 | ||
| + | 102 | == Further reading == | |
| + | 103 | * [[Project:Vendor notability]] — the criteria under which this article exists, and what supplier articles may not contain. | |
| + | 104 | * [[Project:Sourcing guidelines]] — how test reports and community tallies are cited on this wiki. | |
| + | 105 | ||
| 95 | == See also == | 106 | == See also == |
| 96 | * [[Certificate of analysis]] | 107 | * [[Certificate of analysis]] |
| ⋮ | ⋮ | ||
| 100 | * [[Research use only]] | 111 | * [[Research use only]] |
| 101 | * [[Peptide supply chain]] | 112 | * [[Peptide supply chain]] |
| + | 113 | * [[Blind sampling]] | |
| 102 | 114 | ||
| 103 | {{DEFAULTSORT:AmbioPharm}} | 115 | {{DEFAULTSORT:AmbioPharm}} |